CClinicalTrials.gg
SuspendedNCT05262699Updated May 23, 2023

Crossmodal Learning in Therapeutic Processes (Task 2-1)

An interventional study of Vibro-tactile stimulation and Placebo Control in Stroke, sponsored by Universitätsklinikum Hamburg-Eppendorf. Suspended at 1 site in Germany. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-05-23.

Sponsored by Universitätsklinikum Hamburg-Eppendorf · Not applicable, Interventional, and Treatment

Why this study was suspended
Unability to include participants during Covid pandemic

From the registry’s dates

  • Registered 9 months after the study started (first participant enrolled Apr 2021, registered Feb 2022).
Phase
Not applicable
Study type
Interventional
Enrollment
44
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Study summary

Interventional study of the effects of vibro-tactile feedback on behavioral deficits and learning during motor training in patients with stroke.

02

Conditions studied

  • Stroke

Keywords

  • Vibro-tactile stimulation
  • Neurorehabilitation
  • Stroke
03

In context

Lead sponsor

Universitätsklinikum Hamburg-Eppendorf is the lead sponsor of 403 studies on the registry; 83 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Ischemic stroke according to ICD 10 I61-I69
  • Deficit still existing (Rankin score of at least 1 at inclusion)
  • Age >= 18, \<=80
  • Existing declaration of consent

Exclusion criteria

Exclusion Criteria:

  • Pregnancy
  • Lacking capacity for consent
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
44 participants (estimated)

Study arms

  • Experimental
    Stimulation

    During motor training participants in the stimulation arm receive vibro-tactile feedback applied to their fingers when touching an object as measured by force-sensing resistors mounted to the fingertips.

    Device: Vibro-tactile stimulation

  • Placebo comparator
    Control

    The control group receives the same motor training with the same derives (force-sensing resistors, vibro-tactile stimulators) mounted to the hands but receives no stimulation.

    Other: Placebo Control

Interventions

  • DeviceVibro-tactile stimulation

    Vibro-tactile stimulation will be administered to the fingers of the participants via C3 tactors (diameter: 2.03 cm, height: 0.64 cm, operating frequency: 180-320 Hz, see https://www.eaiinfo.com/tactor-info/). Vibro-tactile stimulation will be triggered by force-sensing resistors (TEA CAPTIV T-SENS FSR, see https://www.teaergo.com/products/tea-captiv-t-sens-fsr/).

  • OtherPlacebo Control

    Devices mounted, no stimulation

06

What researchers measure

Primary outcomes

  1. Change from baseline in Action Research Arm Test (ARAT)

    The Action Research Arm Test (ARAT) is a 19 item observational measure to assess upper extremity performance (coordination, dexterity and functioning). Items comprising the ARAT are categorized into four subscales (grasp, grip, pinch and gross movement) and arranged in order of decreasing difficulty, with the most difficult task examined first, followed by the least difficult task. Task performance is rated on a 4-point scale, ranging from 0 (no movement) to 3 (movement performed normally). Scores may range from 0-57 points, with higher points indicating better performance.

    Time frame: One day before (baseline) and one day after seven days of motor training

  2. Change from baseline in Nine-hole peg Test (NHPT)

    A timed measure of fine manual dexterity where the patient is instructed to first take nine pegs out of a container and place them afterwards back into the empty holes of the container as quickly as possible.

    Time frame: One day before (baseline) and one day after seven days of motor training

Secondary outcomes

  1. Change from baseline in Fugl-Meyer Assessment for upper extremity (FMA-UE)

    The section motor function of upper limb is one of five domains, a three-point scale is used for rating performance as 0=cannot perform, 1=performs partially and 2=performs fully, max. possible score: 66 points.

    Time frame: One day before (baseline) and one day after seven days of motor training

  2. Change from baseline in Stroke Impact Scale (SIS)

    Measurement of subjective stroke-specific health status, 64 items in eight domains, domain scores range between 0-100, with higher scores represent better health status.

    Time frame: One day before (baseline) and one day after seven days of motor training

  3. Change from baseline in National Institutes of Health Stroke Scale (NIHSS)

    The National Institutes of Health Stroke Scale, NIHSS, is a score system to quantify the impairment caused by a stroke. The sum of the values from the investigations results in a maximum of 42 points. The higher the score, the more extensive the stroke.

    Time frame: One day before (baseline) and one day after seven days of motor training

  4. Change from baseline in Modified Rankin Scale (mRS)

    The modified Rankin scale (MRS) is a standardized measure that describes the extent of disability after a stroke. It ranges from 0 (no symptoms) to 6 (death due to stroke).

    Time frame: One day before (baseline) and one day after seven days of motor training

07

Study locations

1 site
  • Universitätsklinikum Hamburg-Eppendorf, Neurologie
    Hamburg, 20246, Germany
08

References and documents

Individual participant data

Plan to share: Yes — Data sharing is planned after main publication of results.

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 23, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05262699
Lead sponsor
Universitätsklinikum Hamburg-Eppendorf
Collaborators
German Research Foundation, National Natural Science Foundation of China
Responsible party
Sponsor
First posted
Mar 2, 2022
Start date
Apr 14, 2021
Primary completion
Dec 2024 (estimated)
Completion
Dec 2024 (estimated)
Last update
May 23, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in May 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion